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The membrane topology of the skeletal muscle ryano-
dine receptor (RyRl) was investigated using site-
directed antibodies directed against amino acid se-
quences 2804-2930, 4581-4640, 4860-4886, and 4941-
5037. Ab(2804-2930) bound with identical affinity to ei-
ther closed or permeabilized sarcoplasmic reticulum 
vesicles, confirming the cytoplasmic location of this seg-
ment. Ab(4581-4640) did not bind to closed vesicles but 
bound well to permeabilized vesicles, supporting a lu-
menallocation for this segment. Ab(4860-4886) did not 
bind to closed vesicles but exhibited weak binding to the 
permeabilized vesicles, suggesting that a portion of the 
epitope may be exposed on the lumenal surface. The 
C-terminal antibody (Ab(4941-5037» bound weakly to 
closed vesicles, and binding was not significantly en-
hanced by permeabilizing vesicles with low concentra-
tions of non-denaturing detergent. However, the C-ter-
minal antibodies bound efficiently to vesicles which 
were transiently incubated at alkaline pH or subjected 
to trypsinolysis, conditions where few of the vesicles 
were permeabilized. These results support a model for 
the membrane topology of the ryanodine receptor as 
proposed by Takeshima et al. (Takeshima, H., Nish-
imura, S., Matsumoto, T., Ishida, H., Kangawa, K., Mi-
namino, N., Matsuo, H., Ueda, M., Hanaoka, M., Hirose, 
T., and Numa, S. (1989) Nature 339, 439-445). The results 
also suggest that the native conformation of the C ter-
minus is inaccessible to antibodies. 
The process of excitation-contraction coupling in skeletal 
muscle involves the rapid release of Ca2 + from the sarcoplas-
mic reticulum (SR).l This release is mediated by the ryanodine 
receptor (RyR), a high conductance Ca2 + release channel in the 
SR membrane (1, 2). The RyR functions as a cation-specific 
channel which can be modulated by a variety ofligands including 
Ca2 +, Mg2+, calmodulin, and ATP (2,3). Structurally and func-
tionally related forms of the RyR are also found in cardiac muscle 
(4-6), smooth muscle (7, 8), and brain (9-11). Together with the 
related inositol1,4,5-trisphosphate receptor (IP3R), the RyR iso-
forms represent a distinct family of ligand gated ion channels. 
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The skeletal muscle RyR has been shown to be a high 
molecular weight homotetramer (12-14). The primary se-
quence of the rabbit skeletal muscle isoform (RyR1) has been 
deduced from cDNA cloning (15,16). Each subunit of the RyR 
is composed of 5037 (or 5032) amino acids with a predicted 
molecular mass of -565-kDa, making it one of the largest 
catalytic polypeptides yet identified. Recent studies suggest 
that each high molecular mass subunit may be tightly asso-
ciated with a 12-kDa subunit identified as FK506 binding 
protein, an immunophilin (17). 
The identification and structural characterization of the 
membrane spanning segments of the RyR are central to under-
standing the mechanisms of channel action and regulation. The 
ion conduction pathway is expected to be formed by the mem-
brane-associated portion of the protein. Studies of the IP 3R 
have also implicated the membrane-associated domain as an 
important region for tetramer formation (18, 19). Structural 
studies and sequence analysis of the RyR have suggested that 
only a small region of the protein is integral to the SR mem-
brane. It can also be estimated that approximately 15% or less 
of the total protein mass contributes to the transmembrane 
assembly, based on the low resolution three-dimensional struc-
ture determined from electron microscopy (20, 21). The most 
hydrophobic regions of the sequence, which may correspond to 
membrane spanning segments, are clustered in a domain of 
approximately 1000 residues near the C terminus. The pattern 
of hydrophobic segments in the C-terminal domain is well 
conserved among the three mammalian RyR isoforms (22) and 
across species from mammals to arthropods (23). 
The absence of any identifiable signal sequence at the N 
terminus implies that the large, hydrophilic N-terminal do-
main is localized in the cytoplasm. This is consistent with the 
distribution of mass on the cytoplasmic face of the SR observed 
in electron micrographs (24-26). Several sites in the N-termi-
nal domain have been identified as cytoplasmic. Serine 2843 
has been shown to be the site of phosphorylation by several 
kinases (27). Arginines 426, 1508, 2401, 2840, and 3119 have 
been identified as sites of trypsin cleavage in closed SR vesicles 
(28). An antibody recognizing residues 2-15 at the N terminus 
was also shown to bind to the cytoplasmic face ofSR vesicles (29). 
The membrane topology for the RyR is not yet well defined. 
On the basis of hydrophobicity plots, predictions for the num-
ber of membrane spanning segments range from four (15) to 12 
(16) segments. All of the published models predict an even 
number of membrane spanning segments. Consequently, the 
extreme C terminus is predicted to be cytoplasmic. The cyto-
plasmic localization of the extreme C terminus is supported by 
antibody binding studies of the RyR (29) and the IP3R (30). 
Other sites in the C-terminal domain identified as cytoplasmic 
include a putative regulatory site in the sequence 4489-4499 
identified by antibody binding (31) and tryptic cleavage sites at 
arginine 4475 and arginine 4756 (28). 
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In this study we have used site-directed antibodies to derive 
evidence for the topological location of several segments of the 
ryanodine receptor, in particular in the region predicted to be 
membrane-associated. The differential binding of the antibod-
ies to intact and permeabilized SR vesicles was used to assign 
cytoplasmic or lumenal localization. We show evidence for two 
lumenal segments in the C-terminal domain of the RyR and 
confirm the cytoplasmic localization of the C terminus. In ad-
dition, we provide evidence that the C terminus is folded in an 
inaccessible conformation in the native receptor. 
EXPERIMENTAL PROCEDURES 
Materials-Vent Polymerase was obtained from New England Bio-
labs (Beverly, MA). The protease inhibitor Pefabloc, restriction endo-
nucleases and other DNA modifYing enzymes were obtained from Boeh-
ringer Mannheim. pATH vectors and Escherichia coli strain RR1 were 
obtained from the American Type Culture Collection (Rockville, MD). 
Trypsin (Type III) and the catalytic subunit of cal pain II (rabbit skeletal 
muscle) were obtained from Sigma. Anti-TrpE antibody was obtained 
from Oncogene Science Inc. (Uniondale, NY) and anti-J3-galactosidase 
antibody was obtained from 5 Prime -> 3 Prime Inc (Boulder, CO). 
Anti-calsequestrin (chicken) antibody was a kind gift from Dr. Dennis 
0. Clegg, University of California at Santa Barbara (32). Horseradish 
peroxidase-conjugated anti-rabbit and anti-mouse IgG antibodies were 
obtained from Calbiochem (La Jolla, CAl. Immobilon-P was obtained 
from Millipore Inc. (Bedford, MA). 
Preparation of Heavy SR Vesicles, Junctional Face Membranes, and 
Purification of Ryanodine Receptor-Heavy SR vesicles were prepared 
from the back and leg muscle of rabbits in the presence of protease 
inhibitors as described previously (33). Vesicles were rapidly frozen and 
stored at -80 DC and then thawed immediately prior to use. Junctional 
face membranes (JFM) were prepared by incubating heavy SR vesicles 
in 1 % TritonX-100, 2 mM CaCI2 , pH 7.5, pelleting at 90,000 revolutions/ 
min in a Beckman TLlOO.3 rotor followed by extraction of calsequestrin 
in 0.5 M NaCI, 2 roM EDTA, pH 6.9 (25). Purified RyR was prepared from 
heavy SR vesicles as described previously (12). All preparations were 
carried out in the presence of 20 /-LM leupeptin and either 0.1 mM DIFP 
or 1 roM Pefabloc. Leupeptin was omitted from the final steps of puri-
fication in preparations subsequently subjected to calpain digestion. 
JFM and SR vesicle protein content was determined by BCA assay 
(34) and purified RyR protein content by the Amido Black assay (35). 
Constructs for Expression of Fusion Proteins-All recombinant DNA 
manipulations were carried out by standard procedures (36). Frag-
ments of the RyRl cDNA in pBluescript vectors were prepared by 
antibody screening of a rabbit skeletal muscle cDNA library or by 
reverse transcribed-polymerase chain reaction of rabbit skeletal muscle 
mRNA. Clone CRC6 was provided as a generous gift by Dr. Andrew 
Marks, Mt. Sinai School of Medicine. The trpE fusion construct 
pATH(2804-2930) was produced by ligation of a BglII-PstI fragment of 
clone CRC6, corresponding to RyRl sequence 8539-8919, to PstI di-
gested pATHl (37). Constructs pATH(4581-4640), pATH(4860-4886), 
and pATH(4941-5037) were prepared by polymerase chain reaction 
amplification of RyRl cDNA fragments from positions 13872-14052, 
14709-14790, and 14951-15245, respectively. The polymerase chain 
reaction primers for each sequence included additional sequences at the 
5' end to generate an EcoRI site (forward primers) or HindIII site 
(reverse primers) to facilitate in frame ligation to pATH10 «4581-
4640)) or pATH3 «4860-4886), (4941-5037». The construct pATH-
(5006-5037) was prepared by digestion of the EcoRI-HindIII insert 
from pATH(4941-5037) with HaeIII. The gel purified 103-base pair 
product, corresponding to ryr1 sequence 15147-15245, was ligated to 
SmaI-HindIII digested vector pWR-590-2 (38). The resulting lacZ fu-
sion construct, pWR(5006-5037), was digested with EcoRI-HindIII and 
insert was ligated to EcoRI-HindIII digested pATHl. The sequences 
and reading frames of all the recombinant plasmids were confirmed by 
DNA sequencing (39). The lacZ fusion construct pWR(2804-2930) was 
constructed by EcoRI-HindIII digestion of pATH(2804-2930) followed 
by ligation of the gel purified fragment into EcoRI-HindIII digested 
pWR-590-2. Constructs pWR(4581-4640), pWR(4860-4886), pWR-
(4860-4917), and pWR(4941-5037) were similarly constructed by liga-
tion of EcoRI-HindIII inserts from the corresponding pATH plasmids to 
pWR-590 (38). 
Expression and Purification of TrpE Fusions-The TrpE fusion pro-
teins were prepared by expression in E. coli strain RR1 as described 
(37). Overnight cultures grown in M9 + glucose media containing 
tryptophan were diluted 10-fold into the same media without trypto-
phan and then further induced after 1 h growth by the addition of 5 
/-Lg/ml indoleacrylic acid. Cells were washed in 10 mM Tris-CI, pH 7.5. 
Inclusion bodies were prepared from cultures expressing TrpE(2804-
2930), TrpE(4581-4640), and TrpE(4941-5037). Cleared lysates were 
prepared from cultures expressing TrpE' (no insert DNA), TrpE(4860-
4886), and TrpE(5006-5037) by sonication on ice in 50 mM Tris-CI, 5 
mM EDTA, 0.1% Nonidet P-40, pH 7.5, followed by centrifugation to 
remove insoluble material at 300,000 x g for 15 min. All preparations 
were carried out at 4 DC in the presence of 0.5 mM phenylmethylsulfonyl 
fluoride. The expression of the fusion proteins was confirmed by 10% 
SDS-PAGE. The identity of each expressed protein was confirmed by 
immunoblotting with an anti-TrpE monoclonal antibody. 
Gel purification of fusion proteins was carried out by preparative 
SDS-agarose electrophoresis (ProSieve, FMC BioProducts, Rockland, 
ME). The band corresponding to the fusion protein was identified by 
Coomassie Blue staining of a parallel lane of the gel and excised. The 
excised band was melted at 65 DC in 50 mM Tris-CI, 1 mM EDTA, 0.1% 
SDS, pH 8.0, frozen at -70 DC, thawed at 0 DC, and spun at 14,000 
revolutions/min to remove the agarose. The supernatant containing 
fusion protein was concentrated with a Centriprep-lO concentrator 
(Amicon, Beverly, MA). 
J3-Galactosidase fusion proteins were prepared by expression from 
pWR constructs in E. coli strain MV1189. Overnight cultures of the 
appropriate recombinants were diluted 10-fold in LB media and grown 
for 2 h followed by induction with 1 mM isopropyl-1-thio-J3-D-galactopy-
ranoside. Cells were washed in 10 mM Tris-CI, 0.5 mM phenylmethyl-
sulfonyl fluoride, pH 7.5 and extracted by boiling in SDS denaturing 
buffer. The expression of the lacZ fusion protein was confirmed by 8% 
SDS-PAGE analysis and immunoblotting with a polyclonal anti-J3-
galactosidase antibody. 
Synthetic Peptides and Conjugates-Pep tides corresponding to the 
ryr1 sequences (148-162) and (4965-4979) were prepared by solid-
phase synthesis by Dr. D. Klapper, University of North Carolina. The 
peptides were prepared with an additional N-terminal cysteine to fa-
cilitate coupling. Peptides were coupled to keyhole limpet hemocyanin 
by Immuno-Dynamics Inc. (La Jolla, CAl. 
Preparation of Site-directed Antibodies-A polyclonal antibody 
against the entire rat skeletal muscle RyR has been previously de-
scribed (40). Rabbits were immunized by intramuscular injection of 
antigenic peptides in complete Freund's adjuvant. When the antigens 
were fusion proteins, 300-800 /-Lg of either gel-purified fusion protein or 
bacterial inclusion bodies containing approximately 50% of the desired 
fusion protein were injected. For synthetic peptide antigens, 1 mg of 
each keyhole limpet hemocyanin-conjugated peptide was injected. 
Booster injections were made intradermally and subcutaneously with 
equal amounts of protein in incomplete Freund's adjuvant after 4-6 
weeks and then at 10-14 day intervals. Antisera were collected 10-14 
days post-injection. 
Antisera to fusion proteins were affinity purified by absorption to 
immobilized fusion protein by the method of Lillie and Brown (41). 
Bacterial inclusion bodies (TrpE(2804-2930), TrpE(4581-4640), 
TrpE(4941-5037» or cleared cell lysates (TrpE(4860-4886), TrpE-
(5006-5037» were separated on 10% SDS-PAGE and transferred to 
Immobilon-P membranes (42). The position of the fusion protein band 
was determined by staining a portion of the blot and a strip of the blot 
at that location was cut out from the blot. The strip was blocked in 5% 
non-fat dry milk in PBS and a 0.5-1-ml aliquot of antisera applied to 
the strip for 1-2 h at 25 DC. Nonspecific antibodies were removed by 
washing in PBS-T (phosphate-buffered saline, 0.05% Tween-20). Bound 
antibodies were eluted in 0.5-1 ml of 0.1 M glycine, pH 2.7, which was 
immediately neutralized with 1110 volume of 1 M Tris-CI, pH 8.0. Antisera 
against synthetic peptides were affinity purified using a peptide-agarose 
column prepared using Sulfo-Link gel from Pierce (Rockford, IL). Ap-
proximately 10 mg of each peptide was coupled to a 2-ml column. 
Electrophoresis and Western Blotting-SR protein samples (20-50 
/-Lg) were denatured in Laemmli sample buffer at 100 DC for 3 min and 
separated in 3-12% SDS-polyacrylamide gels by the method of Laemmli 
(43). The following molecular mass standards (kDa) were used: myosin 
(205,000), J3-galactosidase (116), phosphorylase b (97.4), bovine serum 
albumin (66), ovalbumin (45), and carbonic anhydrase (29). The pro-
teins were either stained by the colloidal Coomassie Blue method (44) or 
transferred to Immobilon-P membranes at 400 rnA at 12 DC for 1-3 h 
followed by 1 A for 16 h (45). The membranes were blocked overnight in 
5% nonfat dry milk, PBS, and then incubated with specific antibodies in 
1% milk dissolved in PBS-To After washing in PBS-T, the bound anti-
body was detected with horseradish peroxidase-conjugated anti-rabbit 
or anti-mouse IgG and visualized by incubation with 3,3-diaminoben-
zidine and H 20 2 • 
11340 Ryanodine Receptor Topology and C-terminal Conformation 
-3 
»1\ ~ Ad'" ill ~ IY ~ l ~ I A I ,~M ,~b (\ A Ar;JqJt, ~ = ~ I / YViifVJ(" vrrnJ~'iNvt(~~=o:t 
t,P t t Ca t - -3 
I~~-rlt~~+r~~~~, ~~~-+~~~~~~~~t~-+ 
3000 3500 4000 
II II II 











I I Ref (1S) 
IIII Ref (16) 







FIG. 1. Map of putative transmembrane segments and antigenic peptides in the C-terminal region of the skeletal RyR. First line 
(top), hydrophobicity plot of the C-terminal sequence of the RyR from amino acid 2537-5037 (15) calculated using the scale ofKyte and Doolittle 
(63). Second line, scale bar with amino acid sequence. The location of a cytoplasmic phosphorylation site at serine 2843 (P) (27), a putative 
cytoplasmic calcium regulatory site (Ca) (31), and four cytoplasmic tryptic cleavage sites (t) (28) are indicated. Schematic of the locations of 
predicted membrane-spanning segments are shown as closed bars in the third through fifth lines. Third line, segments M1-M4 predicted by 
Takeshima et al. (15). Fourth line, 12 segments predicted by Zorzato et al. (16). Fifth line, seven of the 10 segments predicted by Brandt et al. (48). 
Sixth line, the locations of sequences used as antigenic peptides (open boxes). The nomenclature of the site-directed antibodies prepared from the 
peptides is indicated below the corresponding boxes. 
Competition ELISA Assay-For detergent permeabilization, SR ves-
icles were incubated in 125 mM Tris-Cl, 750 mM NaCl, pH 7.5, 10 mM 
Pefabloc, 100 /LM leupeptin, 1 mM CaC12 , 1 mM EGTA, and either 0.25 or 
0.1% (w/v) CHAPS at 23°C for 0-60 min, as indicated in the figure 
legends. The vesicles were then diluted 5-fold with deionized water. For 
transient alkalinization, SR vesicles were incubated for 0-60 min in 25 
mM Tris-Cl, 150 mM NaCl, 2 mM Pefabloc, 20 /LM leupeptin, 200 /LM 
EGTA, pH 8.5-9.5 at 23°C. Control SR vesicles were incubated in 
parallel at pH 7.5. At the end of the alkaline incubation, 200 /LM CaC12 
was added, and the alkaline solution was adjusted to pH 7.5 with HCl. 
Control vesicles were incubated in parallel in 25 mM Tris-Cl, 150 mM 
NaCl, 2 mM Pefabloc, 20 /LM leupeptin, 200 ILM CaC12 , 200 /LM EGTA, pH 
7.5, at 23°C. The treated vesicles were serially diluted with 25 mM 
Tris-Cl, 150 mM NaCl, pH 7.5, with or without CHAPS at the same 
concentration in the diluted incubation media. The final concentration 
of detergent in CHAPS-treated samples was :50.06% and the same in 
each titration at all vesicle concentrations. CHAPS did not interfere 
with the binding of antibody to the immobilized RyR at the final con-
centrations used (data not shown). 
To the serial dilutions of either control or treated SR vesicles was 
added an equal volume of antibody solution in 2% dry milk, 25 mM 
Tris-Cl, 150 mM NaCl, pH 7.5. In some experiments 5% normal goat 
serum or 50 J.Lg/ml of cleared bacterial lysate from E. coli expressing the 
TrpE' protein was included in the incubation. These additional blocking 
reagents resulted in a small reduction in the background of the ELISA 
assay but did not significantly change the results of the binding assays. 
The antibodies were incubated with vesicles for 12-16 h at 4°C. Anti-
gen-coated wells were prepared by drying 0.3 /Lg/well of purified RyR 
from deionized water in polystyrene microtiter plates (Falcon) followed 
by fixation with methanol. Alternatively, 5 J.Lglwell of JFM were incu-
bated for 3 h at 23°C in 50 mM NaC03 , pH 9. Coated plates were 
blocked by incubation with 5% dry milk in PBS overnight at 4°C. The 
antibodies not bound to vesicles were detected by adding 100 /Ll of 
antibody-vesicle mixture to antigen-coated microtiter wells for 2 h at 
23°C. The wells were washed thrice with PBS-T and then the antibod-
ies bound to the wells were quantitated using horseradish peroxidase-
conjugated secondary antibody followed by color development with 0-
phenylenediamine. The dilution of each anti-RyR antibody was 
adjusted such that the free antibody concentration in the absence of 
added vesicles produced a signal of approximately 0.05-0.10 OD(490 
nm), within the linear range for detection with the antigen-coated plate. 
The fraction offree antibody was calculated as the ratio of OD(490 nm) 
for antibody incubated with and without SR vesicles. 
Calpain II Digestion of Purified RyR-Calpain II digestions were 
carried out in 100 mM NaCl, 20 mM sodium PIPES, pH 7.5, 2 mM 
dithiothreitol, 4 mM CaC12 , 0.1 mM phenylmethylsulfonyl fluoride, 1 /LM 
pepstatin, 0.1 /LM aprotinin at 23°C. Calpain II (1 unit/ml) was preac-
tivated by incubation for 10 min at 0 °C in 1 mM Ca2 + before addition of 
purified RyR (100 /Lg/ml). Reactions were terminated after 0-60 min by 
the addition of 100 /LM leupeptin and excess EGTA. The preparation of 
rabbit muscle cal pain used in this study (Sigma) had a specific activity 
of 20 units/mg protein. In addition to the 80-kDa catalytic subunit of 
calpain II, the enzyme preparation exhibited significant contamination 
by a protein at -95 kDa. 
Trypsin Digestion of Heavy SR Vesicles-SR vesicles were incubated 
with trypsin at varying SR protein/trypsin ratios in 0.3 M sucrose, 1 mM 
CaC12 , 20 mM potassium PIPES, pH 7.0, for 30 min at 23°C. The 
digestion was stopped by addition of 1.01 volume of 100 mM Pefabloc, 
200 /LM aprotinin, 200 /LM leupeptin, 15 mM EGTA. The digested vesicles 
were then pretreated with 0.1 % CHAPS or at pH 8.5 for 10 min at 23°C 
followed by incubation with antibodies as described above at a final 
concentration of 300 /Lg/ml SR protein. The unbound antibody was 
detected as above. Parallel aliquots of trypsin-digested vesicles were 
analyzed by SDS-PAGE and immunoblotting. 
RESULTS 
Preparation and Characterization of Site-directed Antibod-
ies-The analysis of membrane protein topology based on an-
tibody binding relies on the specificity of the antibodies used. 
For this study, polyclonal antibodies were raised against pep-
tides whose sequences were identical to segments of the de-
duced amino acid sequence of the rabbit skeletal muscle RyR 
(15). The antigenic peptides used in this study are shown 
schematically in Fig. 1. The peptide sequences were selected as 
potential antigens based on the predicted location of trans-
membrane segments (16). Each sequence has a high calculated 
surface probability and antigenic index according to the algo-
rithms of Emini et ai. (46) and Jameson and Wolf (47), respec-
tively. Each antibody was affinity purified by absorption with 
the appropriate peptide antigen. Ab(4941-5037) was further 
purified to higher specificity by absorption to fusion protein 
TrpE(5006-5037) to give Ab(5006-5037). 
The peptide-directed antibodies specifically recognize the 
RyR as indicated by immunoblot analysis of SR proteins (Fig. 
2). The regional specificity of the antibodies was evaluated by 
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FIG. 2. Immunoblot analysis of site-directed antibodies. SR ves-
icles (10 /J-gllane) were solubilized in SDS denaturing buffer, separated 
on 3-12% SDS-PAGE, and stained with Coomassie Blue (lane 1) or 
transferred to Immobilon-P membranes (lanes 2-7) as described under 
"Experimental Procedures". The blots were incubated with the follow-
ing antibodies: Ab(RyR) (lane 2), Ab(2804-2930) (lane 3), Ab(4581-
4640) (lane 4), Ab(4860-4886) (lane 5), Ab(4941-5037) (lane 6), or 
Ab(5006-5037) (lane 7). The mobility of the RyR and molecular mass 
standards (kDa) is indicated. 
examining their reactivity with other RyR fusion proteins and 
proteolytic fragments of the RyR. Four antibodies raised 
against TrpE fusion proteins (Ab(2804-2930), Ab(4860-4886), 
Ab(4941-5037), and Ab(5006-5037» and anti-peptide antibody 
Ab(4965-4979) reacted specifically on immunoblots with [3-ga-
lactosidase fusion proteins expressing the cognate RyR se-
quence (data not shown). 
Calpain II Digestion Pattern-As the [3-galactosidase fusion 
proteins prepared represent only a limited portion of the RyR1 
sequence (307 amino acids), the specificity of the antibodies 
was also probed by examining the reactivity of Ab(2804-2930), 
Ab(4581-4640), Ab(48860-4886), Ab(4941-5037), Ab(5006-
5037), and anti-peptide antibody Ab(4965-4979) with either 
calpain II (Fig. 3) or tryptic (see Fig. 8) fragments of the RyR. 
The calcium-dependent protease calpain II selectively degrades 
the RyR giving rise to a well-defined pattern of fragments 
(48-50). Calpain II digestion of the purified RyR produced 
major fragments of - 400, - 300, - 165, and - 100 kDa which 
were detected on Coomassie Blue-stained gels (Fig. 3A) or by 
immunoblotting with a polyclonal antibody against the intact 
RyR (Fig. 3B). Time course analysis of fragment formation 
suggests that the - 300- and - 100-kDa fragments are produced 
by the breakdown of the - 400 kDa (data not shown). The 
- 165-kDa fragment was recognized specifically by Ab(148-
162) (Fig. 3C), consistent with its previous assignment as the 
N-terminal fragment (48, 50). A secondary fragment of - 150 
kDa is derived from the - 165-kDa fragment (Fig. 3C). The 
- 400-kDa fragment was recognized by Ab(2804-2930) (Fig. 
3D), Ab(4581-4640) (Fig. 3E), and Ab(4941-5037) (Fig. 3F), 
identifying it as the C-terminal fragment. Secondary cleavage 
of the - 400-kDa fragment produced a - 300-kDa fragment 
from the N-terminal portion recognized by Ab(2804-2930) (Fig. 
3D) and a C -terminal 100-kDa fragment recognized by 
Ab(4581-4640) and Ab(4941-5037) (Fig. 3, E and F). Anti-
peptide antibody Ab(4965-4979) reacted with calpain-digested 
fragments of membrane-bound RyR identical to Ab(4941-5037) 
(data not shown). In addition, Ab(4581-4640), Ab(4860-4886), 
and Ab(5006-5037) reacted with previously identified tryptic 
fragments (see Fig. 8, E-G). The pattern of recognition of com-
plementary calpain and tryptic fragments by the antibodies is 
consistent with single-site specificity. 
Binding of Antibodies to Intact and Permeabilized SR Vesi-
cles-Heavy SR vesicles containing the RyR have been shown 
previously to be predominantly oriented with the extravesicu-
lar face corresponding to the cytoplasmic face of the SR (51). 
Permeation studies have also shown that heavy SR vesicles are 
well-sealed (29, 52). The binding of an antibody to heavy SR 
vesicles therefore provides an indication that the epitope rec-
ognized by the antibody is localized on the cytoplasmic face of 
the SR membrane. We tested the ability of antibodies to bind to 
intact and permeabilized SR vesicles. Intact or permeabilized 
SR vesicles at varying concentrations were incubated with 
antibodies and allowed to reach equilibrium. Under the condi-
tions where the antibody concentration is limiting, the binding 
of the antibody to the RyR should deplete the pool of free 
antibodies. The depletion of free antibodies was detected by an 
antibody-capture ELISA assay using microtiter plates coated 
with denatured RyR. 
Antibodies Recognizing Cytoplasmic Epitopes-The anti-
genic peptide recognized by Ab(2804-2930) spans a region in 
the N-terminal domain which contains the cytoplasmic phos-
phorylation site at serine 2843 and a cytoplasmic trypsin cleav-
age site at arginine 2840 (Fig. 1). When incubated with SR 
vesicles, Ab(2804-2930) binds equally well to intact vesicles 
and vesicles permeabilized with the zwitterionic detergent 
CHAPS (0.25%) (Fig. 4A). Similar results are also found for a 
monoclonal antibody, RyRD286, which has been epitope 
mapped to the region 2785-2802.2 The absence of any addi-
tional binding upon permeabilization confirms that the epitopes 
for these antibodies are localized on the cytoplasmic surface of 
the protein. The results also confirm that the vesicles are sub-
stantially oriented with the cytoplasmic face out. An increase in 
binding with permeabilization would be expected if there is a 
significant population of vesicles with inverted orientation. 
Antibodies Recognizing Lumenal Epitopes-Two of the anti-
bodies raised against sequences in the C-terminal domain of 
the receptor, Ab(4581-4640) and Ab(4860-4886), exhibit little 
or no binding to intact vesicles (Fig. 4, B and C). However, there 
was a significant increase in the extent of binding when vesi-
cles were permeabilized with 0.25% CHAPS. The extent of 
binding by Ab(4860-4886) to permeabilized vo::;icles was vari-
able and exhibited low avidity for the soluble RyR as compared 
to denatured RyR. Differential binding with permeabilization 
suggests that the sequences 4581-4640 and 4860-4886 are 
located on the lumenal face ofthe SR membrane. To our knowl-
edge, these results are the first reported evidence for the lu-
menallocation of RyR sequences. 
Antibodies Recognizing the C Terminus-The C terminus of 
the RyR, from position 4941-5037, is predicted to be cytoplas-
mic in the three published topology models. Ab(4941-5037) 
bound to intact vesicles (Fig. 4D). However, the binding was 
significantly less than that observed for Ab(2804-2930) and 
was variable and dependent on the SR vesicle preparation 
(data not shown). Moreover, Ab(4941-5037) exhibited en-
hanced binding to the CHAPS permeabilized SR vesicles (Fig. 
4D). An increase in binding after CHAPS treatment was ob-
served for all preparations tested. The differential binding of 
this C-terminal directed antibody was at variance with the 
results of Marty et al. (29) and was further investigated. 
Since Ab(4941-5037) was raised against a relatively large 
peptide (97 amino acids), the differential binding may reflect 
the polyspecific character of this antibody. Accordingly, a 
smaller peptide corresponding to the sequence of the last 32 
amino acids at the C terminus was used to affinity purify a 
subset of antibodies (Ab(5006-5037» from Ab(4941-5037). In 
addition, we independently prepared Ab(4965-4979) against a 
15-amino-acid peptide corresponding to a hydrophilic sequence 
2 1. Gao and G. Meissner, unpublished results. 
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FIG. 3. Site-directed antibody recognition of calpain II-digested RyR. Purified R yR (100 /.Iog/ml) was dige ted with 1 uniUml cal p ain II. 
The reactions were terminated at the indicated times with the addition of excess EGTA (25 mM ) and leupeptin (100 /.10M ). The reaction were 
denatured in SDS denaturing buffer and separated b y 3-12% SDS-PAGE. A, Coomassie Blue-stained gel. The mobility of molecular mass standards 
(kDa) is indicated to the left. Some of t he RyR migrated as a diffuse band above the position of the RyR monomer. The majority of minor bands 
below 100-kDa in the unproteolyzed (0') lane arose from protein in the calpain preparation. The RyR preparation also contained residua l 
CaATPase, apparent a a band at - 105-kDa. B-G, immunoblot of cal pain-digested R yR with Ab(RyR) (B ), Ab(148-162) (C), Ab(2804-2930) (D ), 
Ab(4581-4640) (E ), and Ab(4941-5037) (F). The predicted molecular weight of the native RyR (565,000) and the estimated molecula r weights of 
the major digestion products are indicated on the dght of panel F. Note that the - 100-kDa fragment is obscured in the Coomassie Blue-stained 
gel shown in A by proteins in the cal pa in II preparation. 
FIG. 4. Antibody binding to intact 
and permeabilized SR vesic les. SR 
vesicles were incubated with (open circles) 
or without (closed circles) 0.25% CHAPS 
at pH 7.5 for 60 min and then diluted, as 
described under "Experimental Pl"Oce-
dures." The final concentration of CHAPS 
after dilution was 0.025% at a ll concen-
trations of CHAPS-treated vesicles. Di-
luted vesicles were incubated at 4 °C for 
16 h with Ab(2804-2930) (A ), Ab(4581-
4640 ) (B ), Ab(4860-4886) (C ), and 
Ab(4941-5037) (D ). The free antibodies 
were detected by binding to denatured 
RyR immobilized on microtiter plates, as 
described under "Experimenta l Proce-
dures." The free antibodies a re equivalent 
to the unbound antibody detected and 
plotted as a fraction of the total antibody 
detected in the absence of SR vesicles. 
Values are means :!: S.E. of two to three 
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in the C-terminal region. The specificity of Ab(4965-4979) was 
confirmed by a characteristic pattern of reactivity on immuno-
blots of SR proteins, RyR cal pain proteolytic fragments, and 
bacterial fusion proteins (data not shown). Additionally, we 
investigated alternative methods for permeabilization of the 
SR vesicles. Extended exposure to alkaline pH in the absence of 
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FIG. S. Differential binding of C-ter-
minai-directed antibodies to intact 
and alkaline-treated SR vesicles. SR 
vesicles were incubated in Tris-buffered 
saline at pH 7.S (closed circles) or pH 8.S 
(open squares) for 60 min. The pH was 
then adjusted to 7.S with Hel, as de-
scribed under "Experimental Proce-
dures." The vesicles were diluted and in-
cubated at pH 7.S with Ab(4941-S037) 
(A), Ab(S006-S037) (B), or Ab(496S-
4979) (e). The free antibodies were de-
tected as in Fig. 4. Values are means :+: 
0.1 10 100 1000 0.1 1 10 100 1000 
SR (~g protein/well) SR (~g protein/weI!) 
S.E. of triplicate determinations of a rep-
resentative experiment. 
calcium renders SR vesicles irreversibly permeable to macro-
molecules (52). Therefore, we examined binding of the C-ter-
minal antibodies to SR vesicles permeabilized by transient 
exposure to pH 8.5 at low calcium. 
Each of the C-terminal-directed antibodies bound poorly to 
the intact vesicles in the preparation of SR shown in Fig. 5. 
Ab(4941-5037) bound well to vesicles treated for 60 min at pH 
8.5 (Fig. 5A). Ab(5006-5037) exhibited a similar differential 
binding to alkaline treated vesicles (Fig. 5B). The binding to 
treated vesicles by Ab(4965-4979) is also increased over binding 
to intact vesicles but does not approach saturation (Fig. 5C), 
presumably due to the lower affinity of this antibody for the 
membrane-bound receptor. The C terminus is therefore exposed 
to antibodies by alkaline treatment as well as by 0.25% CHAPS, 
and this exposure is not peculiar to a single antibody preparation. 
Exposure of the C Terminus: Effect of CHAPS and pH-The 
increase in binding of an antibody under conditions of perme-
abilization may reflect an increase in exposure of an epitope 
which is topologically cytoplasmic but sterically inaccessible 
under native conditions. The detergent CHAPS has been used 
previously to solubilize the RyR with retention of functional 
properties, suggesting that there are no major changes in the 
tertiary or quaternary structure of the solubilized complex (12). 
However, CHAPS may disrupt low affinity interactions with 
other proteins or produce subtle changes in protein structure 
(local denaturation) not detected by functional assays. In order 
to sort out conditions for permeabilization from denaturation, 
we examined the effects of transient exposure of SR vesicles to 
either a low concentration of detergent (0.1 % CHAPS) or alka-
line pH. We examined the effects on vesicle integrity, as gauged 
by the retention and protection of the soluble lumenal SR 
protein calsequestrin. 
SR vesicles were treated with 0.1% CHAPS or at alkaline pH 
(pH 8.5 or 9.5) for 10 min before diluting the detergent 10-fold 
or adjusting the pH to 7.5. The vesicles were pelleted, and the 
release of protein from the vesicles was analyzed by SDS-
c Ab[ 4965-4979] 
0.1 1 10 100 1000 
SR (~g protein/well) 
PAGE. Treatment with 0.1% CHAPS for 10 min resulted in 
only partial solubilization of the RyR. The major portion of 
calsequestrin, however, was released from the vesicles (Fig. 
6B). Permeabilization with 0.3% CHAPS resulted in almost 
complete loss of calsequestrin from the vesicles (data not 
shown). In contrast, transient treatment at pH 8.5 resulted in 
no significant release of calsequestrin in the supernatant, rel-
ative to the untreated vesicles (Fig. 6C). Transient exposure to 
higher pH (pH 9.5) resulted in the partial extraction of calse-
questrin (Fig. 6D). Calsequestrin was also protected from tryp-
tic digestion in untreated vesicles and vesicles subjected to 
transient exposure at pH 8.5, but was accessible to trypsin 
after treatment with 0.1% CHAPS (data not shown). These 
results suggested that the SR permeability barrier toward pro-
teins as small as trypsin (24-kDa) remained substantially intact 
after transient exposure at pH 8.5. In contrast, brief exposure to 
CHAPS as low as 0.1% was sufficient to permeabilize the vesi-
cles. We therefore re-examined the binding of C-terminal-
directed antibodies to CHAPS and alkaline-treated SR vesicles. 
The C terminus becomes accessible to Ab(5006-5037) after 
15 min of exposure to pH 8.5 or 9.5 (Fig. 7A, squares and 
triangles). In contrast, the binding of Ab(5006-5037) to vesicles 
treated with 0.1 % CHAPS is only marginally increased over the 
low level of binding to control vesicles (Fig. 7A, open circles). 
However, the binding to the detergent-treated vesicles tends to 
increase, to a maximal extent of binding equivalent to that of 
pH 8.5-treated vesicles, as the vesicles are held at 0.1 % CHAPS 
for increasing periods of time before dilution (Fig. 7B, open 
circles). The half-time for exposure is -30 min at room temper-
ature. This process is much slower than the rate of partial 
solubilization ofSR vesicles under the same conditions (:510 s), 
as detected by 90°C light scattering (data not shown). The rate 
of detergent-mediated exposure of the C terminus is increased 
by approximately 3-fold when the salt concentration during the 
incubation at 0.1% CHAPS is reduced from 0.75 M NaCl to 0 
(data not shown). 
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FIG. 6. SDS-PAGE analysis of 
CHAPS and alkaline-treated SR vesi-
cles. SR vesicles were treated for 10 min 
at room temperature at pH 7.5 (A ), pH 
7.5,0.1% CHAPS (B ), pH 8.5 (C ), or pH 
9.5 (D) . The incubations were terminated 
by dilution or adjustment of pH to 7.5. An 
aliquot from each incubation was pelleted 
(15 min at 150,000 x g , 4 ec ), and the pel-
lets were resuspended to an equivalent vol-
ume. Equal volumes ofthe total incubation 
mixture (T), supernatant (8 ), and resus-
pended pellet (P ) were solubilized in SDS 
denaturing buffer, separated on 3-12% 
SDS-PAGE, and stained with Coomassie 
Blue. Lanes labeled T contained 10 ",g of 
SR protein. The position of bands con'e-
sponding to RyR (RyR), CaATPase (CA), 
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FIG. 7. Differential binding of site-
directed antibodies to CHAPS and al-
kaline·treated SR vesicles. A and C, 
increasing concentrations of SR vesicles 
were incubated for 15 min at pH 7.5 
(closed circles ), pH 8.5 (squares), pH 9.5 
(triangles), or with 0.1% CHAPS (open cir-
cles ) before adjusting the pH to 7.5 or 
diluting the detergent, respectively. The 
treated vesicles were then incubated with 
90 Ab(5006-5037) (A) or Ab(4581-4640) (C ). 
Values are the mean :!: S.E. of three to 
SR (~g protein/well) incubation time (min) four experiments performed in duplicate. 
Band D, time course of exposure of bind-
C Ab[4581-4640] D Ab[4581-4640] ing sites for Ab(5006-5037) (B ) and 
Ab(4581-4640) (D) . SR vesicles were in-
cubated as in A and C for the indicated 
times at pH 7.5 (closed circles ), pH 8.5 
(squares ), or with 0.1% CHAPS (open cir-
>. >. cles). The first time point in Band D was "d "d 
0 0 taken after 5-10 s which reflects the mix-
,e ,e ing time for the addition of diluent or HC!. r:: r:: 0.5 The treated vesicles were incubated over--< 0.5 « night with antibodies at a final SR protein 
Q) 
Q) 
Q) concentration of 0.3 mg/ml, equivalent to Q) .... .... ... 30 ",g/well SR protein in the ELISA assay . ... 
Values are the mean:!: S.E. of two exper-
0 0 
iments performed in duplicate. 
0.1 10 100 1000 0 30 60 90 
SR (~g protein/well) incubation time (min) 
In contrast to the C terminus, the putative lumenal epitope 
for Ab(4581-4640) is made accessible after very brief exposure 
« 10 s) to 0.1% CHAPS (Fig. 7D, open circles), consistent with 
exposure of the epitope being dependent on permeabilization. 
At reduced salt concentration there is an approximately 40% 
decrease in the rate of detergent-mediated exposure (data not 
shown)_ Transient alkalinization to pH 8.5 results in relatively 
little exposure of the same epitope (Fig. 7, C and D , squares), 
consistent with the observation that this condition does not sub-
stantially permeabilize the SR vesicles (see above). Transient 
alkalinization to pH 9.5 (Fig. 7C, triangles) was nearly as effec-
tive as 0.1% CHAPS in exposing the epitope of Ab(4581-4640). 
Exposure of the C Terminus: Effect of Proteolysis-The re-
quirement for either detergent or pH-mediated denaturation 
for exposure of the C terminus suggests that this region of the 
protein may be buried within the native RyR complex. We 
tested whether this region may become exposed as a conse-
quence of proteolytic degradation of the RyR. Limited tryptic 
digestion of intact SR vesicles resulted in the apparently com-
plete exposure of the epitope for Ab(5006-5037) (Fig. 8A). 
Complete exposure was achieved after digestion for 30 min at 
23 °C at trypsinlSR protein of 1:100 (w/w). The extent of tryp-
sin-dependent exposure was not affected by subsequent treat-
ment with detergent or alkaline pH. In contrast to the C ter-
minus, the putative lumenal epitope for Ab(4581-4640) was 
not exposed by proteolysis alone under the same conditions, but 
could be exposed only after treatment of the proteolyzed vesi-
cles with 0.1% CHAPS (Fig. 8B). Calsequestrin was not de-
graded by trypsin (Figs. 8, C and D), consistent with a previous 
report (28). Therefore, it appears that the permeability barrier 
of the vesicles was not broken down during trypsin digestion. 
After proteolysis at trypsinlSR protein of 1:100 the epitopes for 
Ab(4581-4640) are recovered from the proteolyzed vesicles pri-
marily in fragments of - 76, - 66, and - 37 kDa (Fig. 8E), and 
the epitopes for Ab(4860-4886) and Ab(5006-5037) are recov-
ered as - 76-, - 66-, and - 27-kDa fragments (Fig. 8, F and G, 
respectively). These fragments have been previously identified 
by Callaway et al. (28). The - 76- and - 66-kDa fragments 
appear to be derived from the C terminus by cleavage at argi-
nine 4475 and another undetermined site, respectively. The 
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A B 
Ab(SOO6-5037] Ab(4851-4640) 
FIG. 8. Exposure of C-terminal 
epitopes by trypsin digestion. A and 
B, SR vesicles were incubated with tryp-
sin at the indicated trypsiniSR protein 
(w /w ) ratios for 30 min at 23 · C. The di-
gestion was stopped with the addition of 
trypsin inhibitors. The digested vesicles 
were then incubated at pH 7.5 (closed cir· 
cles), pH 8.5 (squares), or with 0.1% 
CHAPS (open circles) for 10 min. The ves-
icles were diluted or adjusted to pH 7.5, 
respectively, and then incubated with 
Ab(5006 - 5037) (A ) or Ab(4581-4640) (B ) 
at a final concentration of 0.3 mglml SR 
protein. Values are the mean ::!: S.E. of 
two experiments performed in triplicate. 
C, Coomassie Blue-stained 3 -12% SDS-
PAGE of 15 iJ.g of SR proteins from undi-
gested vesicles (- lane) or vesicles di-
gested for 30 min at 23 · C at a trypsinlSR 
protein (w/w ) of 0.01 (+ lane) . Parallel 
samples were blotted with anti-calseques-
trin antibody (D), Ab(4581- 4640) (E ), 
Ab(4860 - 4886) (F) , or Ab(5006 - 5037) 
(G). 
o 0.001 
Trypsin/SR protein (w/w) 
0.01 o 0.001 









- 27-kDa fragment appears to be derived from the C terminus 
by cleavage at arginine 4756, consistent with recognition by 
Ab(4860-4886) and Ab(5006-5037). The - 37-kDa fragment 
appears to be derived from the N-terminal portion of the - 66-
kDa fragment, presumably by cleavage at arginine 4756, con-
sistent with its recognition by Ab(4581-4640). 
DISCUSSION 
Topological Assignment of Epitopes-The present study ex-
amined the topological location of RyR sequences in the C-
terminal portion of the molecule, a region which is believed to 
constitute the channel forming domain of the RyR. The topol-
ogy of several sites was probed by competition ELISA assay 
using site-directed antibodies. Heavy SR vesicles are well ori-
ented, with the extravesicular face corresponding to the cyto-
plasmic side of the SR. The intravesicular space, corresponding 
to the lumen of the SR, was exposed by solubilization of the 
membrane with detergent or by disruption at alkaline pH (52). 
The differential exposure of antibody-binding sites in SR vesi-
cle has been used previously to define a lumenal sequence of 
the SR CaATPase (53). 
However, this approach is confounded by possible effects of 
detergent or alkaline treatment on protein structure, and con-
sequently antibody affinity, independent of permeabilization. 
We have therefore attempted to examine antibody binding 
under conditions in which vesicles are permeabilized with min-
imal disruption of structure or, conversely, conditions in which 
epitopes are exposed by treatments which do not permeabilize 
the vesicles. Our results suggest that two regions including 
amino acids 4581-4640 and 4860-4886 are located in the lumen 
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amino acids 4941-5037 is located on the cytoplasmic face of the 
SR but inaccessible to antibody under native conditions. 
Lumenal Loop 4581- 4640- The sequence recognized by an-
tibody Ab(4581-4640) is predicted by the three published to-
pology models (15, 16, 48) to be a loop located in the lumen of 
the SR. The homologous site is also predicted to be lumenal in 
one model of the IP3R (18) but cytoplasmic in another (30). The 
results of this study are most consistent with a lumenal loca-
tion of the sequence 4581-4640. The antibody binds if and only 
if the SR vesicles are permeabilized. The sequence character-
istics of this region are consistent with a surface accessible 
structure. The sequence is poorly conserved between RyR iso-
forms and between species, in particular in the central region 
from amino acid 4583 to 4627. The sequence identities between 
isoforms in this region are below 20% and there are deletions 
(RyR2, RyR3, and frog alpha) or insertions (Drosophila ) in 
other species and isoforms. The region is hydrophilic and con-
tains a glycine-rich cluster in the middle, consistent with a 
flexible or disordered structure. The remainder of the sequence 
is highly acidic, a property shared by the RyR3 and Drosophila 
isoforms but not by the RyR2 isoform. These features suggest 
that this region may have a functional role related to a high 
density of negative surface charge on the lumenal face of the 
channel, a function not conserved in RyR2. 
Lumenal Loop 4860- 4886-The region from 4860-4878 is 
predicted to be lumenal in the topology models of Takes him a et 
al. (15) and Brandt et al. (48). In contrast, the model of Zorzato 
et al. (16) predicts a cytoplasmic location for this sequence. The 
homologous region is also predicted to be lumenal in one model 
of the IP3R (30) but cytoplasmic in another (18). Our results 
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indicate that Ab(4860-4886) bound, albeit with low apparent 
affinity, to a lumenal site when SR vesicles are permeabilized. 
The region recognized by Ab(4860-4886) is well conserved 
among the RyR isoforms, and the adjacent hydrophobic seg-
ments (4789-4820, 4837-4856, 4879-4898, and 4923-4937) 
are among the most highly conserved sequences between the 
RyR and the IP3R. The IP3R, however, contains a 47-48-ami-
no-acid insertion at a location homologous to tyrosine 4863 of 
the RyR. This inserted sequence, which is highly variable be-
tween IP 3R isoforms, has recently been shown to be located in 
the lumen ofthe ER by antibody labeling and to be glycosylated 
at two sites, consistent with a lumenal localization (54). 
Like the IP3R, the RyR also contains a potential recognition 
site (NKS) for N-linked glycosylation in this region at aspara-
gine 4864. However, glycosylation of the RyR has not been 
detected in lectin overlay studies of SR3 or JFM proteins (55). 
The potential glycosylation site in the RyR falls within a com-
paratively short and well conserved region which may be steri-
cally inaccessible to the ER glycosylation machinery. A rela-
tively inaccessible conformation may explain, in part, the poor 
affinity of Ab(4860-4886) for the native receptor in permeabi-
lized vesicles. That this polar and acidic region is apparently 
located within a confined space may reflect a role as part of the 
conduction pathway, perhaps contributing to the negative sur-
face charge which has been found near the lumenal mouth of 
the channel (56). 
C Terminus 4941-5037: Cytoplasmic and Buried-A recent 
report by Marty et al. (29) found that an antibody directed at 
the last 11 amino acids of the RyR could bind to intact SR 
vesicles, consistent with the predicted cytoplasmic location of 
the C terminus. The results of the current study suggest that 
the binding sites for antibodies directed toward the last 100 
residues of the RyR are relatively inaccessible in SR vesicles 
but are exposed when the vesicles are subjected to several 
treatments including prolonged incubation with detergent, al-
kaline pH, or proteolysis. Exposure of the C terminus under 
conditions where the vesicles are not permeabilized, e.g. by 
trypsin digestion, is consistent with a cytoplasmic localization 
of the C terminus. 
The C terminus is likely to be exposed by conformational 
changes which are related to the structural and functional 
destabilization of the RyR. Limited trypsin digestion, which 
exposes the C terminus, has a dramatic effect on RyR function 
(28,40), despite the apparent retention ofthe tryptic fragments 
in a membrane-bound complex (28,57,58). High NaCl, a con-
dition which favors solubilization of the functional RyR com-
plex in CHAPS (59), renders the solubilized RyR partially 
resistant to trypsin (60) and favors ryanodine binding (2, 3), 
appears to stabilize the C terminus in an antibody-inaccessible 
conformation. 
The apparent inaccessibility of the C terminus in the native 
RyR suggests that this region may be well structured and 
localized either in the folded core of the protein or at a subunit 
interface. The amino acid sequence of this region is well con-
served among the RyR isoforms and contains two hydrophobic 
sequences, suggesting a structurally conserved region. The ab-
sence of protease-sensitive sites in this region (28, 57, 61) is 
also consistent with a buried domain. 
Significance for Topology Models-Four (15), 10 (48), or 
10-12 (16) membrane-spanning segments have been predicted 
for the RyR based on sequence analysis. In addition to seg-
ments in the C-terminal domain, Brandt et al. (48) predicted at 
least four membrane-spanning segments in the N-terminal 
domain. They predict two segments, at amino acids 1514-1530 
3 R. Grunwald and G. Meissner, unpublished results. 
and 1839-1855, based in part on their assignment of the cal-
pain cleavage sites (48). Their cleavage site assignments were 
based in part on hydrophobic affinity labeling using e25I]TID 
(48). However, protein labeling with [125I]TID has been shown 
to occur in hydrophobic regions of proteins which are not mem-
brane associated (62), potentially resulting in the erroneous 
assignments of membrane-associated protein domains. In this 
study we find a different arrangement of secondary calpain 
cleavage sites, based on antibody labeling. We suggest that the 
evidence presented by Brandt et al. (48) does not support the 
prediction the N-terminal membrane-spanning segments. In-
deed, Chen et al. (57) found that a tryptic fragment which 
includes these predicted N-terminal segments was extracted by 
Na2C03, indicating that these segments are not integral to the 
membrane. 
The results of this study support a model with an even 
number of membrane-spanning segments resulting in a cyto-
plasmic C terminus and a cytoplasmic N-terminal domain. The 
four membrane-spanning segments identified as M1-M4 by 
Takeshima et al. (Fig. 1) at positions 4564-4580, 4640-4664, 
4836-4859, and 4918-4937 are consensus predictions of all 
three topology models (Fig. 1). The model of Zorzato et al. (16) 
differs significantly from those of Takeshima et al. (15) and 
Brandt et al. (48) in the prediction of membrane-spanning 
segments at position 4789-4820 and 4879-4898. These seg-
ments have relatively low mean hydrophobicity scores «0.3) 
and as such are weak candidates for membrane-spanning seg-
ments. The evidence for a lumenal location of the region 4860-
4886 presented in this study and the lumenal localization of the 
homologous region in the IP3R (54) suggest that the region in-
cluding 4879-4898 cannot be a membrane-spanning segment. 
The segment predicted by Zorzato et al. (16) at position 
4789-4820 is also unlikely to be a membrane-spanning seg-
ment. If the M3 segment (4836-4859) traverses from cyto-
plasm to lumen, as discussed above, then an adjacent segment 
from position 4789-4820 would have to traverse the mem-
brane from lumen to cytoplasm. Consequently, the region from 
4665-4788 would be predicted to have a lumenal location. 
However, Callaway et al. (28) identified a cytoplasmic tryptic 
cleavage site at arginine 4756. Moreover, the data from this 
study demonstrate the lumenal location of the region 4581-
4640, consistent with the existence of membrane-spanning seg-
ment M2 (4641-4664) which traverses the membrane from 
lumen to cytoplasm. 
There is as yet no direct evidence for additional membrane-
spanning segments beyond the four consensus segments closest 
to the C terminus. The models ofZorzato et al. (16) and Brandt 
et al. (48) predict as many as six additional segments. Indirect 
evidence for the existence of upstream membrane-spanning 
segments comes from the observations of Chen et al. (57) that 
a tryptic fragment which extends from approximately residue 
3370-4475 is retained as an apparently integral membrane 
protein. 
Taken together, the data from the current study and studies 
from other laboratories support a minimal membrane topology 
model for the RyR. The model includes at least four membrane-
spanning segments near the C terminus, corresponding to the 
consensus segments first identified by Takeshima et al. (15) 
from sequence analysis of the skeletal muscle RyR. 
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